Objectives: The present study assessed the predictive value of [
Introduction
The role of induction chemotherapy in the management of advanced head and neck squamous cell carcinoma (HNSCC) remains a matter of debate. Although some studies reported no benefit in terms of survival [1, 2] , it is generally agreed to be useful in organ-sparing strategies and improving quality of life [3, 4] . Response to induction chemotherapy has even been reported to be predictive of radiation therapy response, and complete response to be predictive of disease control [5, 6] .
Even so, it is principally recommended in advanced HNSCC, with variable results; only 70% of laryngeal and hypopharyngeal tumors are chemosensitive [5, 6] . It would therefore be useful to be able to distinguish responder and non-responder subgroups. To that end, early identification of responders and close surveillance of patients receiving this organ-sparing treatment need to be improved.
The role in this context of metabolic functional imaging by [ 18 F]-FDG PET-CT (positron emission tomography with 18-fluoroeoxyglucose radiotracer, coupled to computerized tomography) is currently under assessment. In isolated cervical adenopathy, it has been shown to be effective in locating the primary tumor and detecting metastasis, and for post-treatment surveillance and screening for synchronous tumor in these high-risk patients [7, 8] . It has also been shown to be predictive of tumor reduction under chemotherapy and of survival in esophageal and gastric carcinoma and soft-tissue sarcoma [9] [10] [11] . These various studies demonstrated that a reduction in tumoral metabolic activity exceeding 30-35% on PET-CT was predictive of both tumor chemosensitivity and survival [9] [10] [11] .
The present study assessed the predictive value of PET-CT for tumor response to induction chemotherapy in locally advanced HNSCC. Reduction in SUVmax (maximum standard uptake value) and in hypermetabolic tumor volume between 2 sessions of functional imaging were analyzed. 
Material and method

General principle
This preliminary study assessed the correlation between reduction in SUVmax and in hypermetabolic tumor volume following a first cycle of induction chemotherapy on the one hand, and clinical response at end of therapy on the other. Two [ 18 F]-FDG PET-CT examinations were systematically performed: one prior to initiation and one between the first two cycles (Fig. 1 ).
Inclusion criteria and initial assessment
This retrospective preliminary study included patients with previously untreated, locally advanced stage III or IV HNSCC, eligible for organ-sparing treatment, between November 2010 and November 2012. Initial assessment comprised [ 18 F]-FDG PET-CT, panendoscopy of the head and neck, and biopsies for pathologic analysis. PET-CT systematically preceded biopsy, so as to focus sampling on suspect regions and avoid the false positives incurred by subsequent inflammation.
Therapeutic principle
Patients received 2 or 3 cycles, according to tolerance, of TPF: docetaxel 60 mg/m 2 , cisplatin 75 mg/m 2 and 5FU 750 mg/m 2 [5, 6] . Four or five weeks after the end of induction therapy, clinical response was assessed on endoscopy. Individual treatment continuation by radiochemotherapy or surgery was discussed in multidisciplinary team meeting, depending on clinical response, induction chemotherapy being considered effective for response ≥ 70%.
PET-CT examination and interpretation
[ 18 F]-FDG PET-CT was systematically performed on the Biograph 6 ® LSO PICO 3D PET/CT HI-REZ system (Siemens Medical, Knoxville, TN, USA), in the nuclear medicine department. 18-FDG (4 MBq/kg) was administered intravenously, under fasting and glycemic equilibrium (assessed by capillary glycemia). Images were acquired in 2 steps, 1 hour after injection:
• high-resolution head and neck acquisition comprised CT without contrast enhancement (85 mAs; 130 kV; slice thickness, 3 mm; pitch, 0.85; caredose) followed by 2 16.2-cm PET steps of 10 minutes each, with arms along the body; • thoracic-abdominal-pelvic acquisition comprised CT without contrast enhancement (52 mAs; 130 kV; slice thickness, 5 mm; pitch, 1.5; caredose) followed by 7 or 8 16.2-cm PET steps of 6 minutes each, with arms behind the head.
A dedicated post-treatment console (Leonardo; Siemens) was used for image reading and processing. CT was used for anatomic correlation and to correct PET-image attenuation. For interpretation, the head was realigned along the axis of the hard palate. 
Statistics
The contribution of PET-CT was assessed by comparing reductions in SUVmax and hypermetabolic volume in chemotherapy responders versus non-responders on Mann-Whitney U-test. The significance threshold was set at P < 0.05.
Results
Twenty-one patients were included between 2010 and 2012. Mean age at diagnosis was 56.8 ± 7.1 years (range, 48-67 years), with a sex ratio of 14% female to 86% male. Seventy-one percent (n = 15) presented with piriform sinus tumor and 29% with oropharyngeal carcinoma; there were 12 stage T3 and 9 stage T4 carcinomas. Ninety-five percent of patients showed significant lymph-node involvement: stage N2 or N3 (Table 1) .
Two patients underwent only 1 cycle of chemotherapy, due to onset of infarction and unstable angina.
In 62% (n = 13) of the 21 patients, the neoadjuvant chemotherapy was considered effective, with ≥ 70% tumor reduction on control endoscopy of the upper aerodigestive tract at end of induction ( Table 2 ). The mean interval between first chemotherapy cycle and second PET-CT examination was 15.6 ± 5.4 days.
Mean initial SUVmax was 17.98 ± 3.31 in responders, versus 15.93 ± 6.22 in non-responders (P = 0.3).
Responders showed a significantly greater mean SUVmax reduction between PET-CT examinations: 46.3 ± 25.03% (Fig. 2) , versus 21.6 ± 12.9% in non-responders ( Fig. 3 ) (P = 0.04). PET-CT precision for a 30% SUVmax reduction threshold during chemotherapy was thus 0.67, with a positive predictive value of 0.75. Non-responders tended to show greater reduction in hypermetabolic volume than responders, but without significant difference: 50.1 ± 28.2 and 42.7 ± 32.5, respectively (P > 0.05) ( Table 3) .
In accordance with the treatment protocol, non-responders underwent surgery. Pathologic examination of operative and lymph-node dissection specimens systematically confirmed the diagnosis of HNSCC. In contrast, pathologic analysis of biopsy samples from patients free of tumor at the end of chemotherapy (i.e., with 100% response) found no residual HNSCC.
Discussion
Assessing response to induction chemotherapy is a major issue in the treatment and prognosis of advanced head and neck squamous cell carcinoma [2, 4] . Consensual criteria are morphological, Fig. 2 . PET-CT in a responder to induction chemotherapy. based on endoscopy and CT or MRI. CT and MRI assessment of tumor volume reduction on the RECIST system (Response Evaluation Criteria in Solid Tumors), however, is complicated by inflammation and tumoral necrosis. Tumor volume assessed on imaging shows large inter-observer variation [12, 13] , and imaging is of no early predictive value with regard to response to chemotherapy.
To be able to predict the efficacy of induction chemotherapy and thus reduce toxicity, biomolecular and genetic studies are ongoing: human papillomavirus (HPV) infection and especially the presence of protein p53 and mRNA of oncoproteins E6 and E7 in oropharyngeal squamous cell carcinoma seem to be factors of good prognosis and good response to radiochemotherapy. In France, however, HPV infection is found in only 11.5-26% of cases of HNSCC [14] . ERCC1 gene expression and DPD (dihydropyrimidin dehydrogenase) cyclin D1 mutations [15, 16] also offer interesting possibilities. There are, however, no validated biomolecular or genetic tests in current use.
In this context, PET-CT offers an interesting predictive criterion for induction chemotherapy response: SUVmax reflects tumor metabolic activity during induction chemotherapy and can detect changes in tumor metabolism even ahead of morphologic changes, and without the need for biopsy or surgery. According to the present preliminary results, a reduction of more than 30% in SUVmax in locally advanced HNSCC is predictive of good response to chemotherapy (P = 0.04). To the best of our knowledge, there have been few studies of PET-CT as a predictor of induction chemotherapy response in HNSCC [17] [18] [19] . In 2005, Yen et al. demonstrated efficacy in predicting nasopharyngeal tumor response: only 1 out of 25 responders experienced recurrence, versus 15 out of 27 non-responders [18] . In 2012, Kikuchi and Abgral also demonstrated the role of PET-CT in assessing induction chemotherapy response in HNSCC. Discrepancies between these two studies, however, raise the issue of the SUVmax reduction threshold defining tumor response: 55% for Kikuchi [17] , but 25% for Abgral [19] . In gastric and esophageal carcinoma, many studies Table 3 PET-CT data in chemotherapy responders and non-responders. have reported a predictive role for PET-CT, with positive predictive values ranging from 77% to 93% and negative predictive values from 83% to 95% [9] [10] [11] ; these studies reported SUVmax reductions of 30-35% to be predictive of good (> 70%) chemotherapy response. The present preliminary results agree on this cut-off value. More than 30% reduction in SUVmax was observed in 3 non-responders: image analysis in these cases, however, on the one hand found that SUVmax reduction was no greater than 30-40%, and moreover that the lesions in question were very voluminous and highly necrotic. PET-CT results are thus to be interpreted with caution in large tumors. A larger sample would probably confirm this finding, and new criteria taking account of both SUVmax and volume are probably required for precise assessment of treatment response on PET-CT. PET-CT has also been compared with conventional imaging: in several studies, CT and MRI were found to be less informative than [ 18 F]-FDG PET-CT [20] . In 2009, Chepeha et al. showed PET-CT to be in "substantial" agreement with endoscopy ( = 0.62), compared to merely "fair" agreement for CT ( = 0.4) for the assessment of chemotherapy response in oropharyngeal carcinoma. Another study, of 19 HNSCC patients, found a significant difference in SUVmax reduction after chemotherapy between responders (82%) and non-responders (32%; P = 0.01); the same study reported a non-significant difference in tumor volume reduction on CT (80% and 41%, respectively; P = 0.09) [21] . MRI led to the same conclusions: > 55% reduction in SUVmax between diagnosis of HNSCC and end of chemotherapy was significantly predictive of complete response, with 95% specificity and 86% sensitivity; tumor volume reduction on MRI, on the other hand, showed no significant findings (P = 0.12) [22] . Likewise, hypermetabolic tumor volume assessment on the present technique of threshold determination by predetermined isocontours did not emerge as predictive of chemotherapy response. Even so, although this fixed threshold method seems unsuited to the analysis of chemotherapy response, we consider it indispensable to evaluate other hypermetabolic volume thresholding methods, adapted to the individual patient, with variable SUV isocontours. Determining a reliable hypermetabolic volume on PET-CT during chemotherapy would help optimize strategy, especially with regard to surgery.
Conclusion
[ 18 F]-FDG PET-CT is now widely accepted and recommended for extension assessment in nasopharyngeal carcinoma and primary adenopathy. Indications in other head and neck tumors remain a matter of debate, and recommendations are cautious [23] , notably due to practical issues of equipment access; applications in chemotherapy could revive interest in this attitude. The present preliminary study demonstrated that the rate of early reduction in SUVmax exceeding 30% during induction chemotherapy differed significantly between responders and non-responders. A larger scale study is needed to determine a more reliable cut-off. Other metabolic volume thresholding techniques should also be assessed. The use of [ 18 F]-FDG PET-CT could prevent the cumulative toxicity of iterative chemotherapy in relatively non-responsive subjects, who could benefit from earlier screening to receive adapted treatment more promptly.
